Lyell Immunopharma Inc (LYEL) USD0.0001

Lyell Immunopharma, Inc. is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. The Company has only one product candidate, LYL314, in Phase I/II clinical development. LYL314 is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. LYL314 is designed with a true 'OR' logic gate to target B cells that express either CD19 or CD20 with full potency and is manufactured with a process that enriches for CD62L-positive cells to generate more naive and central memory CAR T cells with enhanced stemlike features and antitumor activity.